UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

~~the~~ Securities Exchange Act of ~~1934~~ 1934

Date of Report (Date of earliest event reported): ~~November 8~~December 14, 2012

DUSA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

New Jersey

001-31533

22-3103129

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

25 Upton Drive

Wilmington, Massachusetts 01887

(Address of principal executive offices, including ZIP code)

(978) 657-7500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Securities Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 18.01 ~~Entry~~Other ~~into a Material Definitive Agreement~~Events.

~~On November 8, 2012,~~ DUSA Pharmaceuticals, Inc.® (~~the~~NASDAQ ~~“Company”~~GM: DUSA), ~~entered~~is ~~into~~reporting preliminary anresults ~~Agreement~~of ~~and~~a ~~Plan~~Phase 2 clinical trial investigating the use of ~~Merger~~the (Levulan® Kerastick® in conjunction with BLU-U® blue light illumination for the ~~“Merger~~treatment ~~Agreement”~~of actinic keratoses (AKs) byof the face and ~~among~~scalp ~~the~~when ~~Company,~~utilizing ~~Sun~~short ~~Pharmaceutical~~drug incubation. The study demonstrated that treatment ~~Industries~~with ~~Limited~~Levulan ~~(“Sun~~Kerastick ~~Pharma”)~~— after incubating for one, atwo ~~corporation~~or ~~organized~~three ~~under~~hours ~~the~~— ~~laws~~resulted in a statistically significant number of ~~India,~~patients with complete lesion clearance and ~~Caraco~~a ~~Acquisition~~statistically ~~Corporation~~significant ~~(“Acquisition~~reduction ~~Sub”),~~in aAK ~~New~~lesion ~~Jersey~~count ~~corporation~~when ~~and~~compared ~~indirect~~to treatment ~~wholly-owned~~with ~~subsidiary~~vehicle of12 ~~Sun~~weeks ~~Pharma~~post treatment.

~~Under~~The ~~the~~multi-center, ~~terms~~randomized, ofblinded, ~~the~~vehicle-controlled ~~Merger~~study ~~Agreement,~~across 13 ~~Acquisition~~trial ~~Sub~~sites ~~will~~enrolled ~~commence~~ a ~~tender~~total ~~offer~~of ~~(the~~235 ~~“Offer”)~~subjects and followed them for up to ~~purchase~~six ~~all~~months. ofThe ~~the Company’s~~results ~~outstanding~~showed ~~shares~~that ofat ~~common~~12 ~~stock~~weeks, noafter ~~par~~receiving ~~value~~up ~~per~~to ~~share~~2 ~~(“Common~~photodynamic ~~Stock”~~therapy (PDT) treatments, atsubjects atreated ~~purchase~~with ~~price~~Levulan® using incubation times of ~~$8.00~~1, ~~per~~2, ~~share~~or 3 hours all demonstrated similar degrees of efficacy, ~~without~~with ~~interest~~up to 79% AK lesion clearance rates, ~~net~~while subjects receiving vehicle alone had up to ~~the~~a ~~seller~~14% inlesion ~~cash~~clearance. (Analysis of the ~~“Offer~~24 ~~Price”).~~week ~~The~~follow ~~Merger~~up ~~Agreement~~data ~~provides~~ showed that ~~the~~up ~~Offer~~to ~~will~~78% ~~expire~~of 20subjects ~~business~~treated ~~days~~using ~~following~~broad ~~the~~area, ~~commencement~~short drug incubation (BASDI) who were completely clear of AK ~~the~~lesions ~~Offer,~~at ~~subject~~12 toweeks ~~certain~~remained ~~extension~~free ~~rights~~of ~~and~~lesions ~~obligations~~at ~~set~~24 ~~forth~~weeks. inThis ~~the~~compares ~~Merger~~to ~~Agreement~~13% of subjects treated using a spot application method.

The ~~Offer~~safety isprofile ~~conditioned~~seen ~~upon, among other things, there being validly tendered~~ in ~~the~~this ~~Offer~~study ~~shares~~is ofconsistent ~~Common Stock that, together~~ with ~~shares~~what ofhas ~~Common~~been ~~Stock~~seen ~~owned~~in byprevious ~~Sun~~clinical ~~Pharma,~~studies ~~Acquisition~~involving ~~Sub~~Levulan® PDT orand ~~any of their respective affiliates (the “Sun Group”), represent a majority of the outstanding Common Stock on a fully diluted basis (the “Minimum Tender Condition”). The Offer~~ is ~~also~~similar ~~subject~~ to ~~certain~~that ~~other~~seen ~~conditions,~~in ~~including (i)~~ the ~~representations~~current ~~and~~labeling. There ~~warranties~~were ofno ~~the~~treatment-related ~~Company~~serious ~~set~~adverse ~~forth~~events inreported ~~the Merger Agreement are true and correct or,~~ in ~~certain cases, except where~~ the ~~failure~~study ~~of such representations or warranties to be so true~~ and ~~correct~~only ~~(individually~~one ~~or in the~~subject ~~aggregate)~~did ~~would~~ not ~~reasonably~~complete bethe ~~likely~~study. toThe ~~have~~study autilized ~~Company Material Adverse Effect (as defined in~~ the ~~Merger~~Levulan® Kerastick® ~~Agreement);~~ (~~ii)~~aminolevulinic ~~the~~acid ~~expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976; (iii~~HCl) ~~the~~ ~~Company’s~~for ~~compliance,~~Topical ~~in all material respects~~Solution, 20% with ~~its obligations under~~ the BLU-U® ~~Merger~~Blue ~~Agreement;~~Light ~~and~~Photodynamic ~~(iv)~~Therapy ~~the~~Illuminator ~~absence~~which ofis ~~certain~~FDA ~~legal~~approved ~~impediments and other customary conditions. The date of payment~~ for ~~shares of Common Stock accepted for payment pursuant to and subject to~~ the ~~Offer~~treatment ~~conditions~~of isminimally ~~referred~~ to moderately asthick ~~the~~actinic ~~“Offer~~keratoses ~~Closing.”~~(AKs) ~~Neither~~of the ~~Offer~~face ~~nor~~or ~~the Merger is subject to a financing condition~~scalp.

~~The~~Except ~~Merger~~for ~~Agreement~~historical ~~provides~~information, ~~among~~this ~~other~~report ~~provisions,~~contains certain forward-looking statements that ~~subject~~represent toour ~~certain~~current ~~terms~~expectations and ~~conditions~~beliefs ~~set~~concerning ~~forth~~future ~~in the Merger Agreement~~events, ~~Acquisition~~and ~~Sub~~involve ~~will~~certain ~~merge~~known ~~with~~ and ~~into~~unknown ~~the~~risk ~~Company~~and ~~(the “Merger”)~~uncertainties. ~~after~~These ~~the~~forward-looking ~~Offer.~~statements ~~The~~relate ~~date~~to safety and ~~time~~efficacy atresults ~~which~~of the trial. These ~~Merger~~forward-looking ~~becomes~~statements ~~effective~~are isfurther ~~the~~qualified ~~“Effective~~by ~~Time,”~~important ~~which~~factors ~~may~~that ~~occur~~could atcause ~~any~~actual ~~time~~results ~~following~~to ~~the~~differ ~~Offer~~materially ~~Closing,~~from ~~subject~~future toresults, ~~the~~performance ~~right~~or ofachievements ~~the~~expressed ~~parties~~or toimplied ~~terminate~~by ifthose in the ~~Offer~~forward-looking ~~Closing~~statements ~~has~~made ~~not~~in ~~occurred~~this byrelease. These ~~August~~factors 8include, ~~2013.~~without Atlimitation, ~~and~~actions ~~following~~by ~~the~~health ~~Effective~~regulatory ~~Time~~authorities, ~~the~~clinical ~~separate~~trial ~~corporate~~risks ~~existence~~and ~~of Acquisition Sub will cease~~results, ~~and~~ the ~~Company~~status ~~will~~of ~~continue~~our aspatent ~~the~~portfolio, ~~surviving~~reliance ~~corporation~~on inthird ~~the Merger. As a result of the Merger~~parties, ~~each~~ ~~issued~~ and ~~outstanding share of Common Stock (~~other ~~than~~risks ~~shares~~and uncertainties ofidentified ~~Common Stock held by the Sun Group or the Company, or held~~ in ~~the Company~~DUSA’s ~~treasury,~~Form ~~that~~10-K isfor ~~not tendered pursuant to~~ the ~~Offer)~~year ~~will~~ended ~~be converted into the right to receive~~December 31, ~~as merger consideration, an amount in cash equal to the Offer Price, without interest~~2011.

If after the purchase of the Common Stock pursuant to the Offer and giving effect to the Top-Up (described below), if applicable, the Sun Group owns at least 90% of the outstanding Common Stock on a fully-diluted basis, then, following the satisfaction or waiver of the other conditions to the closing of the Merger, Sun Pharma will effect a Merger pursuant to applicable New Jersey Business Corporation Law, which will not require the consent of the Company’s

shareholders. The Merger is also conditioned upon the absence of certain legal restraints and the acceptance of payment by Acquisition Sub of all the shares of Common Stock validly tendered pursuant to the Offer. Pursuant to the Merger Agreement, if the Minimum Tender Condition is satisfied but Sun Pharma and Acquisition Sub do not own at least 90% of the Common Stock then outstanding, but would, after exercise of the Top-Up Option, own in the aggregate at least one share more than 90% of the Common Stock then outstanding, the Company will issue to Acquisition Sub, and Acquisition Sub will purchase (the “Top-Up”), at a price per share equal to the Offer Price, up to a number of newly issued, fully paid and nonassessable shares of Common Stock (the “Top-Up Shares”) that, when added to the number of shares of Common Stock directly or indirectly owned by Acquisition Sub at the time of the closing of the purchase of Top-Up Shares (after giving effect to the Offer Closing), will constitute one share more than 90% (determined on a fully diluted basis) of the shares of the Common Stock outstanding immediately after the issuance of the Top-Up Shares.

Pursuant to the Merger Agreement, if the 90% threshold referred to in the two preceding paragraphs is not satisfied and the Top-Up is not permitted under applicable law or the terms of the Merger Agreement, the Company will cause a special meeting of the Company’s shareholders for the purpose of voting on the adoption of the Merger Agreement and the approval of the Merger.

The Company has made customary representations, warranties and covenants in the Merger Agreement, including among others, covenants not to solicit alternative transactions or to provide information or enter into discussions in connection with alternative transactions, except with respect to discussions or negotiations with persons related to certain bona fide, unsolicited written acquisition proposals, and subject to certain limited exceptions to permit the Company’s board of directors to comply with its fiduciary duties.

Effective upon the Offer Closing, assuming the Minimum Tender Condition is met, Acquisition Sub will be entitled to certain rights to appoint board directors as will give the Acquisition Sub majority representation on the board.

The Merger Agreement contains certain termination rights for the Company and Sun Pharma, and further provides that, upon termination of the Merger Agreement under certain specified circumstances, the Company will be obliged to pay Sun Pharma a termination fee of $9,000,000.

This summary of the principal terms of the Merger Agreement and the copy of the Merger Agreement filed as an exhibit to this Form 8-K are intended to provide information regarding the terms of the Merger Agreement and are not intended to modify or supplement any factual disclosures about the Company in its public reports filed with the Securities and Exchange Commission. In particular, the Merger Agreement and the related summary are not intended to be, and should not be relied upon as, disclosures regarding any facts and circumstances relating to the Company. The foregoing description of the Offer, Merger and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1 and is incorporated into this report by reference.

The consummation of the Offer will result in an acceleration of the vesting of all outstanding and previously unvested stock options and restricted stock awards issued pursuant to the Company’s Amended and Restated 2011 Equity Compensation Plan and the 1996 Omnibus Plan, as amended.

A copy of the Merger Agreement is provided with this report solely to inform investors of its terms. The Merger Agreement contains representations and warranties by the Company, on the one hand, and by Sun Pharma and Acquisition Sub, on the other hand, made solely for the benefit of the other. The assertions embodied in those representations and warranties are qualified by certain disclosures, not contained in the Merger Agreement, that modify, qualify and create exceptions to the representations and warranties set forth in the Merger Agreement. Moreover, certain representations and warranties in the Merger Agreement were made as of a specified date, may be subject to a contractual standard of materiality different from what might be viewed as material to shareholders or may have been used for the purpose of allocating risk between the Company, on the one hand, and Sun Pharma and Acquisition Sub, on the other hand. Accordingly, investors should not rely on the representations and warranties in the Merger Agreement as characterizations of the actual state of facts about the Company, Sun Pharma or Acquisition Sub at the time they were made or otherwise.

Item 3.01 Unregistered Sales of Equity Securities.

In connection with the Company’s entry into the Merger Agreement, the Company granted to Acquisition Sub the Top-Up option, which under certain circumstances would permit Acquisition Sub to purchase, at a price per share equal to the Offer Price, up to a number of newly issued, fully paid and nonassessable shares of Common Stock that, when added to the number of shares of Common Stock directly or indirectly owned by Sun Pharma and its subsidiaries at the time of the closing of the purchase of Top-Up Shares (after giving effect to the Offer Closing), will constitute one share more than 90% (determined on a fully diluted basis) of the shares of the Common Stock outstanding immediately after the issuance of the Top-Up Shares.

Item 3.03 Material Modification to Rights of Security Holders.

The consummation of the Offer will result in an acceleration of the vesting of all previously issued but unvested stock options and restricted stock awards issued pursuant to the Company’s Amended and Restated 2011 Equity Compensation Plan and the 1996 Omnibus Plan, as amended.

Item 8.01. Other Matters

On November 8, 2012, the Company issued a press release announcing the execution of the Merger Agreement, a copy of which is attached as Exhibit 99.1 hereto and incorporated herein by reference.

Important Additional Information Will Be Filed with the Securities and Exchange Commission

This current report is not an offer to purchase or a solicitation of an offer to sell any securities of the Company. The Offer has not yet been commenced. Upon commencement of the Offer, Sun Pharma and Acquisition Sub will file a Tender Offer Statement on Schedule TO

containing an offer to purchase and related materials, and the Company will mail to the Company’s shareholders a solicitation/recommendation statement with respect to the Offer on Schedule 14D-9. The Company’s shareholders are urged to read these materials carefully when they become available since they will contain important information, including the terms and conditions of the Offer. The Company’s shareholders may obtain a free copy of these materials (when available) and other documents filed by Sun Pharma, Acquisition Sub or the Company with the SEC at the website maintained by the SEC at www.sec.gov. The offer to purchase and related materials, the solicitation/recommendation statement, the Schedule TO, and the Schedule 14D-9 may also be obtained (when available) for free by contacting the information agent for the Offer (when one is selected).

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements. These statements are not guarantees of future performance or assurances of an expected course of action, and therefore, readers should not put undue reliance upon them. Some of the statements that are forward-looking include statements of belief or intent predicated on the Company’s expectations for strategic opportunities. There are a large number of factors that can cause the Company to deviate from plans or to fall short of expectations. As to the forward-looking matters contained in this report, factors that can cause such changes include our ability to respond timely and in accordance with the laws applicable to the Company and its board of directors. The Company’s business as a whole is subject to a number of risks, and to the extent those risks are known to be material, they have been listed and discussed in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2011, and quarterly reports on Form 10-Q. Please note that forward-looking statements are current as of today. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

ITEM 9.01. Financial Statements and Exhibits

(d) Exhibits

2.1		Merger Agreement dated November 8, 2012.
99.1		Press Release dated November 8, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUSA PHARMACEUTICALS, INC.

Dated: November 8, 2012

/s/ Robert F. Doman

Dated: December 14, 2012

/s/ Robert F. Doman

Robert F. Doman, President and

Chief Executive Officer

Filing Compare · DUSA PHARMACEUTICALS INC